AMAG Pharmaceuticals, Inc. AMAG Income Statement

Amag pharmaceuticals, inc. (AMAG)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Sep'09	Jun'09
Revenue from Contract with Customer [Abstract]
Revenues:
Revenues
68,661	89,707	84,131	78,109	75,804	88,123	122,238	146,254	117,387	-	124,331	130,371	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product sales, net
-	-	-	-	-	-	-	-	-	-	-	-	112,517	-	115,777	102,983	89,564	90,832	88,917	84,652	77,415	46,982	23,009	22,484	17,523	-	19,347	17,456	-	-	-	-	-	-	15,802	13,081	11,022	-	15,173	16,226	13,295	3,009	0
Service revenues, net
-	-	-	-	-	-	-	-	-	-	-	-	26,931	-	27,965	24,379	19,520	-	7,177	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other revenues
-	-	-	-	-	-	-	-	-	-	-	-	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License fee, collaboration and other revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	40	57	216	948	58	39,232	12,090	6,271	2,485	2,318	3,312	3,108	1,998	2,055	2,003	6,564	1,566	16,592	1,753	1,999	1,707	2,288	2,327	-	1,684	2,529	-	-	0
U.S. Feraheme product sales, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15,578	-	16,186	14,094	13,626	-	-	-	-	-	-	-	-	-	-
Other product sales and royalties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	271	138	299	199	-10	326	101	-	-	-	-	-	-	-	-	-	-
Royalties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46	33	36	-	35	72	11	12	55
Total revenues
-	-	-	-	-	-	-	-	-	-	-	-	139,472	-	143,782	127,419	109,300	108,735	96,152	123,884	89,505	53,253	25,494	24,802	20,835	21,711	21,616	19,649	17,880	21,144	17,742	31,012	15,480	14,907	17,555	15,402	13,385	17,220	16,892	18,827	13,306	3,021	55
Costs and expenses:
Cost of product sales
24,359	43,321	21,105	24,290	18,477	28,715	46,489	76,776	63,912	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of product sales
-	-	-	-	-	-	-	-	-	-	-	-	27,573	-	25,706	21,937	18,300	18,716	19,088	19,679	21,026	11,758	2,968	2,743	2,837	3,326	2,547	3,145	2,942	4,027	4,323	3,224	2,646	2,739	2,669	2,082	3,041	2,438	2,274	1,884	1,010	128	0
Cost of services
-	-	-	-	-	-	-	-	-	-	-	-	5,010	-	4,984	5,195	5,526	-	3,261	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development expenses
11,180	16,477	15,330	14,980	18,066	12,211	10,133	11,693	10,809	11,996	16,274	30,258	16,489	19,982	17,116	14,234	14,229	7,897	19,809	8,184	6,988	7,764	5,358	4,540	6,498	6,581	4,530	4,049	5,404	7,903	5,260	7,671	12,462	12,985	14,894	16,695	13,566	13,279	14,031	14,784	12,368	6,109	10,114
Acquired in-process research and development
0	0	0	0	74,856	0	12,500	0	20,000	0	0	5,845	60,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling, general and administrative expenses
52,697	68,874	65,720	77,324	74,682	66,030	72,451	15,898	73,431	36,865	11,962	58,900	70,424	-2,847	57,216	51,924	63,175	50,255	46,141	31,801	32,112	27,521	10,958	16,284	17,491	15,017	14,934	15,211	14,005	12,629	12,160	15,101	13,181	15,173	17,230	16,826	19,634	19,493	17,986	24,004	23,456	19,351	17,268
Impairment of Intangible Assets, Finite-lived
-	-	0	77,400	-	-	0	0	-	-	319,246	-	-	-	0	15,963	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition-related costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,500	2,653	-	-	1,917	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restructuring expenses
0	20	0	0	7,400	0	0	0	0	-	-	-	-	-370	0	89	622	2,384	738	443	571	-	-	-	-	-	-	-	-	-	562	1,058	-	-	-	-	-	-	-	-	-	-	-
Total costs and expenses
88,236	283,650	102,155	193,952	193,501	106,956	141,573	104,367	168,152	114,441	378,567	127,104	179,496	31,192	105,022	109,342	101,852	86,062	97,537	62,760	60,697	56,627	21,201	23,567	26,826	25,706	22,011	22,405	22,351	25,154	22,305	27,054	28,289	34,405	34,793	35,603	36,241	37,434	34,291	40,672	36,834	25,588	27,382
Operating loss
-19,575	-193,943	-18,024	-115,843	-117,697	-18,833	-19,335	41,887	-50,765	-12,846	-254,236	3,267	-40,024	20,794	38,760	18,077	7,448	22,673	-1,385	61,124	28,808	-3,374	4,293	1,235	-5,991	-	-395	-2,756	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense):
Interest expense
6,604	6,510	6,419	6,330	6,450	6,572	13,366	16,056	15,977	15,979	16,847	17,256	18,300	18,151	18,309	18,250	18,443	18,457	14,222	10,205	10,367	7,041	3,129	3,051	1,476	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) on Extinguishment of Debt
-	-	0	-	-	-	-35,922	-	-	-	-314	-9,516	-	-	0	0	-	-	-10,449	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and dividend income
477	635	840	1,224	1,586	2,121	1,612	952	643	629	487	663	1,031	830	838	773	708	545	524	372	71	166	291	253	265	278	246	256	271	260	295	338	393	357	378	452	560	418	448	404	471	503	783
Gains on marketable securities, net
-	-	263	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gains on investments, net
-	-	-	-	-	-	-	-	-	-	-	-	27	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
1,311	131	-45	2	340	-11	-19	-44	0	-	0	-69	-	-7	-24	0	220	-	-9,182	2	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other (expense) income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,495	-17,477	-17,515	-	-33,329	-9,831	-10,296	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gains on sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	566	299	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gains (losses) on investments, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	26	6	-	2	-1,471	-	1	14	-209	1	6	-396	794	4	-319	275
Fair value adjustment of settlement rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-788	-	321	-185
Total other expense, net
-4,816	-6,007	-5,361	-5,104	-4,524	-4,462	-47,695	-15,148	-15,334	-16,474	-16,674	-26,178	-17,242	-	-	-	-	-	-	-	-	-	-2,835	-2,782	-1,111	-	250	848	576	263	297	-1,133	393	358	392	243	561	424	52	410	475	505	873
Loss before income taxes
-24,391	-	-	-	-122,221	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from continuing operations before income taxes
-	-	-23,385	-120,947	-	-23,295	-67,030	26,739	-66,099	-29,320	-270,910	-22,911	-57,266	3,466	21,265	600	-10,067	4,753	-34,714	51,293	18,512	-10,151	1,458	-1,547	-7,102	-	-	-	-	-	-4,266	2,825	-	-	-16,846	-19,958	-	-19,790	-17,347	-21,435	-23,053	-22,062	-26,454
Income tax expense (benefit)
100	-10	200	-100	-137	-2,500	-2,400	52,600	-8,000	-30,738	-115,197	-8,659	-20,706	9,475	5,069	1,196	-2,540	-2,448	-14,130	18,035	5,608	-	-	-	-	-	-	-	-	-	-299	-494	-	-	-215	-396	-	-	-351	-111	-	-	0
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
-	-	-23,617	-120,827	-	-20,745	-64,678	-25,817	-58,099	-	-155,713	-14,252	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax
-	-	0	0	-	-1	5,838	7,158	5,878	-	4,506	373	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of CBR business
-	-	0	-	-	-	89,581	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense
-	-	0	0	-	-974	-98	1,422	2,021	-	854	187	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent
-	-	0	0	-	-1,532	95,517	5,736	3,857	-	3,652	186	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-24,491	-199,928	-23,617	-120,827	-122,084	-22,277	30,839	-20,081	-54,242	3,459	-152,061	-14,066	-36,560	-10,556	16,196	-596	-7,527	7,201	-20,584	33,258	12,904	143,008	1,458	-1,547	-7,102	-3,654	-145	-1,908	-3,895	-3,686	-3,967	3,319	-12,416	-18,581	-16,631	-19,562	-22,295	-	-16,996	-21,324	-	-22,062	-26,454
Total (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.30	0.47	-0.02	-0.22	0.10	-0.62	1.09	0.47	6.39	0.07	-0.07	-0.33	-	-0.01	-	-	-	-	0.16	-	-	-	-0.92	-	-	-	-	-1.15	-1.29	-1.55
Total (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.26	0.43	-0.02	-0.22	0.34	-0.62	0.82	0.39	5.79	0.06	-0.07	-0.33	-	-0.01	-	-	-	-	0.15	-	-	-	-0.92	-	-	-	-	-1.15	-1.29	-1.55
Loss from continuing operations (in dollars per share)
-	-	-0.70	-3.57	-	-0.59	-1.88	-0.75	-1.70	-	-4.41	-0.41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.09	-0.18	-	-0.19	-	-0.58	-	-0.78	-	-1.05	-	-0.81	-	-	-	-
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share
-	-	0.00	0.00	-	-0.04	2.77	0.17	0.11	-	0.10	0.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic and diluted net loss per share (in dollars per share)
-0.72	-5.90	-0.70	-3.57	-3.54	-0.63	0.89	-0.58	-1.59	0.06	-4.31	-0.40	-1.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.01	-	-	-
Weighted Average Number of Shares Outstanding, Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	34,251	34,171	34,223	34,739	34,812	33,223	30,636	27,213	23,931	21,984	21,925	21,824	-	21,691	-	-	-	-	21,370	-	-	-	21,167	21,144	-	21,085	21,017	19,985	17,117	17,038
Weighted average shares outstanding used to compute net loss per share (basic and diluted) (in shares)
34,104	-	33,906	33,807	34,469	-	34,492	34,358	34,162	-	35,311	35,145	34,378	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,603	21,544	-	21,403	-	21,349	-	21,194	-	-	-	-	-	-	-	-
Weighted Average Number of Shares Outstanding, Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	28,259	42,111	34,223	34,739	26,583	33,223	43,181	38,245	33,684	23,467	21,925	21,824	-	21,691	-	-	-	-	21,649	-	-	-	21,167	21,144	-	21,085	21,017	19,985	17,117	17,038
Product Sales
Revenues
68,628	73,378	84,107	77,976	75,729	88,047	122,238	146,219	117,348	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other revenues
Revenues
33	-71	24	133	75	76	0	35	39	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-